Pharma News

Nine-valent HPV vaccine "hard to get a shot" Expert: Waiting? you don't have to

2022-01-23: In recent days, there has been widespread concern about the tight supply of the nine-priced HPV vaccine for women between 16 and 26 years of age, as well as the fact that the vaccine has been on the queue for more than six months, and the introduction of vaccination shaker policies in some areas,…  

Advanced tumors are expected to usher in more new drugs!

2022-01-22: Tumours in [pharmaceutical network industry dynamics] are localized diseases that affect the whole body, and because early symptoms are not visible, many of the patients are found to be late, and the data show that late tumours account for about 70 per cent of the cases of malignant tumours. The…

The annual report performance of 8 pharmaceutical companies is good! 1 net profit increased by over 1000 percent

2022-01-22: On January 22, the annual announcement of companies listed in the pharmaceutical bio-industry continued to be disclosed, largely on a pessimistic basis. Prospective pharmaceutical companies include Koto Medicine, Magic Pharmaceuticals, Rohin Pharmaceuticals, Luxurious Pharmaceuticals, and the…

Domestic innovative drugs usher in a big outbreak, where is the way out for generic drugs?

2022-01-22: As national policies increasingly focus on pharmaceutical innovation, the development of our pharmaceutical innovation industry has begun to accelerate. It is understood that, in order to seize new market development opportunities, pharmaceutical companies are now increasingly investing in…

Is the Covid medicine coming? The pharmaceutical and biological sector plummeted! The king of demon kings fell by the limit, and the northeast Yaomao fell by the limit for three consecutive days

2022-01-21: On the morning of 21 January, deep concussions came down and the Covid-19 test plate went down for a while. By mid-noon, the medical biology index had fallen by 2.92%, the “King of the Evil King” medical treatment had fallen, and the “Northeast Pharmacy” had fallen for three consecutive days. On…

The cutting is constantly messed up! The annual report of Tai'antang was untrue and was subject to administrative supervision by consolidating the sold company

2022-01-21: In the first year of the year, after China's Economic Network (journalist Guo Wenpe) issued a circular on 21 January, the Da An and its controlling shareholder, the Tai An Church, received three copies of the Decision on Administrative Regulatory Measures - the Tai An Church was ordered to take…

The market of traditional Chinese medicine formula granules ushered in new opportunities, and the upstream "shovel sellers" can be tapped

2022-01-21: [Pharmanet Market Analysis] In recent years, as ageing and “Healthy China 2030” have advanced, demand for Chinese medicines has continued to grow, and advantages such as the ease with which Chinese formulations are used have become more market-friendly. At the same time, the penetration rate of…

Under the steady growth of the market, the API industry will usher in new opportunities for development

2022-01-20: The raw materials pharmaceutical industry is about to develop a new opportunity. Currently, the production of raw materials continues to grow as a result of the increase in large numbers of patented end-of-date medicines, the increase in generic drug varieties and increases in the number of…

What kind of human suffering is dysmenorrhea? How can those who have not survived understand

2022-01-20: There's a hot topic for discussion in Weibo: “What kind of human suffering is it?" Some say that “every time you come to aunts, there's a feeling that there's a lot of super-big vans that run over your stomach”, others “want to break off their whole stomachs, throw out garbage cans, crush them…

Luye Pharma's Compound Analgesics Report

2022-01-20: In recent days, the Board of Directors of Greenleaf Pharmaceuticals Group Ltd. announced that the group's application for a listing permit in the area of pain relief in the study of the products of hydroxycodone Narcotone (LY021702) had been accepted by the Drug Review Centre of the National Drug…

Huadong Medicine's DR30303 for injection was approved for clinical use

2022-01-20: On 20 January, the Washington Medicines Bulletin stated that, on 18 January, the Daol Biology, a subsidiary of the East China Pharmaceutical Holdings, received the approval of the National Drug Control Authority for the approval of a pharmaceutical clinical trial (No. 2022LP00075), and that the…

Daiichi Sankyo spins off 8 cardiovascular drugs, shifts focus to oncology portfolio

2022-01-20: In recent days, a third-combined pharmaceutical programme announced the sale of US rights to eight cardiovascular drugs to Cosette Pharmaceuticals in New Jersey. This initiative is part of a five-year medium-term strategy for the third-combined pharmaceutical industry, which aims to transform the…

Chia Tai Tianqing adalimumab biosimilar approved for marketing

2022-01-20: On 20 January, Chinese biopharmaceuticals (1177.HK) announced that Tybowij (Adam wood single anti-injection fluid) being produced by the core companies under the banner had been officially approved by the National Drug Supervisory Authority for the treatment of three major adaptive conditions,…

This week, a group of pharmaceutical companies spent huge sums of money to launch large-scale mergers and acquisitions!

2022-01-20: In recent years, major pharmaceutical companies have opened up a “buy-and-buy” model in response to the impending expiry of the original drug, the patent cut-off, increased competition in the industry, and the decline in the profits of generic pharmaceuticals. So far, less than a month into 2022,…  

The traditional Chinese medicine sector reappears! Multiple stocks rose more than 3 percent

2022-01-20: On January 20, the Chinese medicine board re-emerged, with an increase of more than 10 per cent in the enlightenment industry, an increase of almost 10 per cent in the fine pharmaceuticals industry, an increase of more than 6 per cent in the Yong Tinjin pharmaceutical industry and an increase of…

Tianjing Bio-CD47 Monoclonal Antibody Starts Phase II Clinical Trial in China, Combining with PD-1 for Advanced Solid Tumors

2022-01-20: In recent days, it has been officially announced that the innovative CD-47 (Lemzoparlimab, also known as TJC4) that it has developed autonomously has completed the first case of drug delivery from a Chinese “basket” clinical study (NCT05148533) for the treatment of late-stage physical tumours, in…

Biositu and Xingyeon reached a cooperation to jointly develop immune cell therapy drugs

2022-01-20: Recently, in a public announcement issued at the official level, Paositu announced that a strategic cooperation agreement had been reached with Starling (Shanghai) Biotech Co. Ltd. (“Shangang”), which would be based on the platform of RenMabella mice to produce all-man antibody molecules, and…  

Ascletis Pharma and Lao Pharmaceutical Company Sign Purchase Agreement for Ritonavir Tablets

2022-01-20: Recently, Google Pharmacy announced at a public address that Lao Phokam Pharmacional Import-Export Co., Ltd. (buyer) and Gyorei Pharmaceutical Ltd. (seller) had signed the Litonave purchase agreement. Litonavi oral film is a drug-degenerative booster for a variety of oral antiviral drugs for viral…

Henlius BRAF V600E Inhibitor HLX208 Approved for Phase Ib/II Clinical Trials

2022-01-20: In recent days, the HLX 208 inhibitor BRAF V600E has been published as an announcement that Ib/II clinical trials have recently been approved by the National Drug and Monitoring Service for single medications or combined treatment of late-stage physical tumours of BRAF V600E or BRAF V600 mutant…

Hengrui's innovative drug camrelizumab esophageal cancer research results published in The Lancet

2022-01-20: Recently, the results of the multi-centre II clinical study (CAP 02), led by Prof. Xing Xingxia and Prof. Wang Feng, First Annex Hospital, Chuenzhou University, on the joint Apadeni II treatment of terminal dietary cancer, were published in the magazine Lancet Gastroenterology & Hepatology (Lancet…  

Load More


Trending in China

What China Reads


Pharma News


Nine-valent HPV vaccine "hard to get a shot" Expert: Waiting? you don't have to

2022-01-23: In recent days, there has been widespread concern about the tight supply of the nine-priced HPV vaccine for women between 16 and 26 years of age, as well as the fact that the vaccine has been on the queue for more than six months, and the introduction of vaccination shaker policies in some areas,…  

Advanced tumors are expected to usher in more new drugs!

2022-01-22: Tumours in [pharmaceutical network industry dynamics] are localized diseases that affect the whole body, and because early symptoms are not visible, many of the patients are found to be late, and the data show that late tumours account for about 70 per cent of the cases of malignant tumours. The…

The annual report performance of 8 pharmaceutical companies is good! 1 net profit increased by over 1000 percent

2022-01-22: On January 22, the annual announcement of companies listed in the pharmaceutical bio-industry continued to be disclosed, largely on a pessimistic basis. Prospective pharmaceutical companies include Koto Medicine, Magic Pharmaceuticals, Rohin Pharmaceuticals, Luxurious Pharmaceuticals, and the…

Domestic innovative drugs usher in a big outbreak, where is the way out for generic drugs?

2022-01-22: As national policies increasingly focus on pharmaceutical innovation, the development of our pharmaceutical innovation industry has begun to accelerate. It is understood that, in order to seize new market development opportunities, pharmaceutical companies are now increasingly investing in…

Is the Covid medicine coming? The pharmaceutical and biological sector plummeted! The king of demon kings fell by the limit, and the northeast Yaomao fell by the limit for three consecutive days

2022-01-21: On the morning of 21 January, deep concussions came down and the Covid-19 test plate went down for a while. By mid-noon, the medical biology index had fallen by 2.92%, the “King of the Evil King” medical treatment had fallen, and the “Northeast Pharmacy” had fallen for three consecutive days. On…

The cutting is constantly messed up! The annual report of Tai'antang was untrue and was subject to administrative supervision by consolidating the sold company

2022-01-21: In the first year of the year, after China's Economic Network (journalist Guo Wenpe) issued a circular on 21 January, the Da An and its controlling shareholder, the Tai An Church, received three copies of the Decision on Administrative Regulatory Measures - the Tai An Church was ordered to take…

The market of traditional Chinese medicine formula granules ushered in new opportunities, and the upstream "shovel sellers" can be tapped

2022-01-21: [Pharmanet Market Analysis] In recent years, as ageing and “Healthy China 2030” have advanced, demand for Chinese medicines has continued to grow, and advantages such as the ease with which Chinese formulations are used have become more market-friendly. At the same time, the penetration rate of…

Under the steady growth of the market, the API industry will usher in new opportunities for development

2022-01-20: The raw materials pharmaceutical industry is about to develop a new opportunity. Currently, the production of raw materials continues to grow as a result of the increase in large numbers of patented end-of-date medicines, the increase in generic drug varieties and increases in the number of…

What kind of human suffering is dysmenorrhea? How can those who have not survived understand

2022-01-20: There's a hot topic for discussion in Weibo: “What kind of human suffering is it?" Some say that “every time you come to aunts, there's a feeling that there's a lot of super-big vans that run over your stomach”, others “want to break off their whole stomachs, throw out garbage cans, crush them…

Luye Pharma's Compound Analgesics Report

2022-01-20: In recent days, the Board of Directors of Greenleaf Pharmaceuticals Group Ltd. announced that the group's application for a listing permit in the area of pain relief in the study of the products of hydroxycodone Narcotone (LY021702) had been accepted by the Drug Review Centre of the National Drug…

Huadong Medicine's DR30303 for injection was approved for clinical use

2022-01-20: On 20 January, the Washington Medicines Bulletin stated that, on 18 January, the Daol Biology, a subsidiary of the East China Pharmaceutical Holdings, received the approval of the National Drug Control Authority for the approval of a pharmaceutical clinical trial (No. 2022LP00075), and that the…

Daiichi Sankyo spins off 8 cardiovascular drugs, shifts focus to oncology portfolio

2022-01-20: In recent days, a third-combined pharmaceutical programme announced the sale of US rights to eight cardiovascular drugs to Cosette Pharmaceuticals in New Jersey. This initiative is part of a five-year medium-term strategy for the third-combined pharmaceutical industry, which aims to transform the…

Chia Tai Tianqing adalimumab biosimilar approved for marketing

2022-01-20: On 20 January, Chinese biopharmaceuticals (1177.HK) announced that Tybowij (Adam wood single anti-injection fluid) being produced by the core companies under the banner had been officially approved by the National Drug Supervisory Authority for the treatment of three major adaptive conditions,…

This week, a group of pharmaceutical companies spent huge sums of money to launch large-scale mergers and acquisitions!

2022-01-20: In recent years, major pharmaceutical companies have opened up a “buy-and-buy” model in response to the impending expiry of the original drug, the patent cut-off, increased competition in the industry, and the decline in the profits of generic pharmaceuticals. So far, less than a month into 2022,…  

The traditional Chinese medicine sector reappears! Multiple stocks rose more than 3 percent

2022-01-20: On January 20, the Chinese medicine board re-emerged, with an increase of more than 10 per cent in the enlightenment industry, an increase of almost 10 per cent in the fine pharmaceuticals industry, an increase of more than 6 per cent in the Yong Tinjin pharmaceutical industry and an increase of…

Tianjing Bio-CD47 Monoclonal Antibody Starts Phase II Clinical Trial in China, Combining with PD-1 for Advanced Solid Tumors

2022-01-20: In recent days, it has been officially announced that the innovative CD-47 (Lemzoparlimab, also known as TJC4) that it has developed autonomously has completed the first case of drug delivery from a Chinese “basket” clinical study (NCT05148533) for the treatment of late-stage physical tumours, in…

Biositu and Xingyeon reached a cooperation to jointly develop immune cell therapy drugs

2022-01-20: Recently, in a public announcement issued at the official level, Paositu announced that a strategic cooperation agreement had been reached with Starling (Shanghai) Biotech Co. Ltd. (“Shangang”), which would be based on the platform of RenMabella mice to produce all-man antibody molecules, and…  

Ascletis Pharma and Lao Pharmaceutical Company Sign Purchase Agreement for Ritonavir Tablets

2022-01-20: Recently, Google Pharmacy announced at a public address that Lao Phokam Pharmacional Import-Export Co., Ltd. (buyer) and Gyorei Pharmaceutical Ltd. (seller) had signed the Litonave purchase agreement. Litonavi oral film is a drug-degenerative booster for a variety of oral antiviral drugs for viral…

Henlius BRAF V600E Inhibitor HLX208 Approved for Phase Ib/II Clinical Trials

2022-01-20: In recent days, the HLX 208 inhibitor BRAF V600E has been published as an announcement that Ib/II clinical trials have recently been approved by the National Drug and Monitoring Service for single medications or combined treatment of late-stage physical tumours of BRAF V600E or BRAF V600 mutant…

Hengrui's innovative drug camrelizumab esophageal cancer research results published in The Lancet

2022-01-20: Recently, the results of the multi-centre II clinical study (CAP 02), led by Prof. Xing Xingxia and Prof. Wang Feng, First Annex Hospital, Chuenzhou University, on the joint Apadeni II treatment of terminal dietary cancer, were published in the magazine Lancet Gastroenterology & Hepatology (Lancet…  

Load More